Evolus, Inc. 8K

Evolus, Inc. announced strong Q2 2026 results with continued positive adjusted EBITDA, raised its 2026 financial guidance, and expanded its injectable aesthetics portfolio and global licensing footprint, including new rights to Profhilo in the U.S. and broader Estyme distribution.

Evolus, Inc. reported its second quarter 2026 results, highlighting 21% year-over-year net revenue growth to $84.1 million, a GAAP operating loss of $4.5 million, and its third consecutive quarter of positive adjusted EBITDA of $4.7 million, while raising full-year 2026 guidance for net revenue, adjusted gross margin, and narrowing non-GAAP operating expense guidance. The company emphasized strong commercial momentum for its injectable aesthetic portfolio, including Jeuveau and Evolysse, successful European launch of its Estyme hyaluronic acid gel collection, and expanded exclusive licensing agreements with Symatese for Estyme in Canada, Australia, and New Zealand, as well as a new exclusive U.S. licensing and distribution agreement with IBSA for Profhilo. Evolus expects HA gels to contribute 10%–12% of 2026 revenue, reaffirmed its 2028 long-term outlook of $450–$500 million in net revenue and 13%–15% adjusted EBITDA margins, and stated it remains focused on advancing Evolysse Sculpt through FDA review while maintaining adequate liquidity with $45.2 million in cash and additional non-dilutive capacity of about $120 million.

Filing Facts

CIK

1570562

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-053384

Alert Tier

6